Tailoring therapeutic strategies for advanced non-small-cell lung carcinoma (NSCLC) relies on identifying specific biomarkers, such as programmed death ligand 1 (PD-L1) expression in tumor cells and the presence of oncogenic addictions like epidermal growth factor receptor (EGFR) mutations. This evidence concerns the gene CD274 and neoplasm.